SUBSEQUENT EVENTS	3 Months Ended
Mar. 31, 2025
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 11 SUBSEQUENT EVENTS The Company has analysed its operations subsequent to May 15, 2025 through the date these financial statements were issued, and other than those listed below, has determined that it does not have any material subsequent events to disclose. On April 1, 2025, the Company issued 6,000,000 Common Stock warrants under its employee stock option plan to an employee with an exercise price of $0.089. On April 4, 2025, the Company issued 400,000 shares of Common Stock in exchange for $32,800 per the terms of the SEPA. On April 14, 2025, the Company issued 300,000 shares of Common Stock in exchange for $23,705 per the terms of the SEPA. On April 18, 2025, the Company issued 600,000 shares of Common Stock in exchange for $48,660 per the terms of the SEPA.

SUBSEQUENT EVENTS

3 Months Ended

Mar. 31, 2025

NOTE 11 SUBSEQUENT EVENTS

The Company has analysed its operations subsequent to May 15, 2025 through the date these financial statements were issued, and other than those listed below, has determined that it does not have any material subsequent events to disclose.

On April 1, 2025, the Company issued 6,000,000 Common Stock warrants under its employee stock option plan to an employee with an exercise price of $0.089.

On April 4, 2025, the Company issued 400,000 shares of Common Stock in exchange for $32,800 per the terms of the SEPA.

On April 14, 2025, the Company issued 300,000 shares of Common Stock in exchange for $23,705 per the terms of the SEPA.

On April 18, 2025, the Company issued 600,000 shares of Common Stock in exchange for $48,660 per the terms of the SEPA.

Kraig Biocraft Laboratories, Inc 10-Q